Authors

Latest:

Dr. Champiat on Early Efficacy of SOT101 Plus Pembrolizumab in Solid Tumors

Stéphane Champiat MD, PhD, discusses early efficacy seen with the combination of SOT101 and pembrolizumab in solid tumors.

Piotr Rutkowski, MD

Latest:

Dr Rutkowski on the Safety Profile of Avelumab Plus Axitinib in GIST

Piotr Rutkowski, MD, discusses the safety and clinical implications of avelumab in combination with axitinib in unresectable or metastatic GIST

Kara N. Maxwell, MD, PhD

Latest:

Dr Maxwell on Cancer Risk for Males Carrying Germline BRCA Mutations

Kara N. Maxwell, MD, PhD, discusses the risk of cancer for males carrying BRCA mutations.

Alvaro Alencar, MD

Latest:

Dr Alencar on the Rationale of Investigating BTK Degraders in CLL

Alvaro Alencar, MD, explains the rationale of a phase 1 trial investigating NX-5948, a BTK degrader, in chronic lymphocytic leukemia.

Logan Roof, MD

Latest:

Dr Roof on Disparities in Lung Cancer Mortality Rates in the United States

Logan Roof, MD, discusses findings from a study investigating trends in lung cancer mortality across different sociodemographic populations and locations in the United States between 1999 and 2020.

Catriona Jamieson, MD, PhD, University of California San Diego

Latest:

Dr. Jamieson on Treatment Considerations in Myelofibrosis

Catriona Jamieson, MD, PhD, discusses treatment considerations for patients with myelofibrosis.

Scott R. Solomon, MD

Latest:

Dr. Solomon on the Rationale For Liso-Cel in Relapsed/Refractory LBCL

Scott R. Solomon, MD, discusses the rationale for examining lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Thomas M. Habermann, MD

Latest:

Dr Habermann on Ongoing Trials in MCL and MZL

Thomas M. Habermann, MD, discusses ongoing clinical trials in mantle cell lymphoma and marginal zone lymphoma.

Madappa Kundranda, MD, PhD

Latest:

Leveraging Immunotherapy in GI Malignancies: Looking to the Future

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.

Jean-Philippe Theurillat, MD

Latest:

Dr. Theurillat on Castration and AR Inhibition in Prostate Cancer

Jean-Philippe Theurillat, MD, discusses castration and androgen receptor inhibition in prostate cancer.

Wenxin (Vincent) Xu, MD

Latest:

Final Thoughts/Looking Forward

Tae Kon Kim, MD, PhD

Latest:

Dr. Kim on the Synergistic Effect of PD-1H Blockade in AML

Tae Kon Kim, MD, PhD, discusses key results on the synergistic effects of PD-1H blockade in acute myeloid leukemia..

Brian Ball, MD

Latest:

Dr Ball on Prior Research Supporting the SELECT-AML-1 Trial in Newly Diagnosed AML

Brian C. Ball, MD, discusses previous research on tamibarotene in newly diagnosed acute myeloid leukemia, and how these data support the ongoing phase 2 SELECT-AML-1 trial.

Allison Butts, PharmD, BCOP

Latest:

Breast Cancer Treatment: Sequencing With Antibody-Drug Conjugates

Clinical pearls regarding ways to integrate antibody-drug conjugates into treatment algorithms when managing patients with breast cancer.

Stephen L. Rose, MD

Latest:

Dr. Rose on the Importance of Genetic Testing in Ovarian Cancer

Stephen L. Rose, MD, UW Health, discusses the importance of genetic testing in ovarian cancer.

Nicole Concin, MD

Latest:

Dr. Concin on the Patient Population in the LIO-1 Trial in Advanced Gynecologic Malignancies

Nicole Concin, MD, discusses the patient population that enrolled in the phase 1b/2 LIO-1 trial in advanced gynecologic malignancies.

Bradley Monk, MD, FACOG, FACS

Latest:

Endometrial Carcinoma: Clinical Case Scenario 3

Oncologists debate the proper treatment of a patient with a grade 2 endometrial carcinoma tumor.

Anne M. Noonan, MBBCh

Latest:

Dr Noonan on Challenges Regarding the Sequencing and Selection of Therapies in HCC

Anne M. Noonan, MBBCh, discusses unmet needs that remain to be addressed in hepatocellular carcinoma, including challenges regarding the navigation and sequencing of treatment options

Monica H. Vetter, MD

Latest:

Dr Vetter on the Role of Trial Inclusion Criteria on Coverage for Pembrolizumab- and Dostarlimab-Based Regimens in Endometrial Cancer

Monica H. Vetter, MD, on the implications for inclusion criteria for insurance approvals for pembrolizumab- and dostarlimab-based regimens in endometrial cancer.

Rino S. Seedor, MD

Latest:

Dr. Seedor on Treatment Sequencing in Metastatic Melanoma

Rino S. Seedor, MD, discusses findings from the phase 3 DREAMseq trial, which solidified up-front immunotherapy followed by targeted therapy upon progression as a standard of care in patients with BRAF V600–mutant metastatic melanoma.